Clinical and diagnostic features of pertussis in older children

Попова, О. П.; Мазанкова, Л. Н.; Skirda, T A; Bunin, S. V.; Власов, Е. В.

doi:10.21508/1027-4065-2019-64-4-70-75

Ross. vestn. perinatol. pediatr.

2019

DOI: 10.21508/1027-4065-2019-64-4-70-75

|View full text |Cite

Clinical and diagnostic features of pertussis in older children

О. П. Попова

Л. Н. Мазанкова

T A Skirda

et al.

Abstract: В статье представлен анализ клинико-диагностических особенностей коклюша у детей старшего возраста. Удельный вес данной возрастной группы среди госпитализированных составлял 11,3±2,7–13,3±2,7% с преобладанием привитых против этой инфекции больных. У 93,6±3,6% пациентов заболевание протекало в среднетяжелой форме с типичным симптомокомплексом. Для верификации клинического диагноза был использован метод полимеразной цепной реакции (ПЦР) и серологический метод – иммуноферментный анализ (ИФА). Эффективность метода… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates

Kostinov,

Polishchuk,

Ryzhov

et al. 2024

Annals RAMS

View full text Add to dashboard Cite

Background. Given the high prevalence of Bordetella pertussis, patients with respiratory disorders are at risk of getting infected with this pathogen and developing pertussis. Therefore, they should be considered a target group for vaccination against this infection. Aims — the objective of the study was to assess vaccine-induced immunity against pertussis in lung transplant candidates. Methods. Twenty-four patients with severe bronchopulmonary diseases, aged 18 to 60, were vaccinated against pertussis with Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine. Five patients underwent lung transplantation. Immunoglobulin G (IgG) antibodies (Abs) were measured using the RIDASCREEN® Bordetella IgG test system. Results. In the post-vaccination period, only 8.3% of the patients developed such local reactions as tenderness and induration at the injection site. The proportions of patients who were seropositive for pertussis before vaccination, one month and one year after vaccination were 71, 100 and 100%, respectively (p = 0.02). A significant increase in anti-pertussis IgG Ab levels was identified one month after a single vaccine dose, and was still observed after 12 months. In the group of two-dose vaccination, there was no statistical difference between the levels of IgG Abs one month after the first dose and one month after the second dose. A significant increase in anti-Bordetella pertussis IgG Ab levels was observed in the group of initially seronegative patients compared to seropositive patients (p = 0.03). A year after vaccination, there was no statistically significant difference in IgG Ab levels between the patients with and without a history of lung transplantation. Conclusions. The majority (71%) of patients with severe bronchopulmonary disease was seropositive for B. pertussis. Single-dose vaccination against pertussis was safe; it induced the production of additional specific Abs and an increase in their levels in all patients. Therapy administered after lung transplantation did not significantly affect the levels of vaccine-induced Abs.

show abstract

Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates

Kostinov,

Polishchuk,

Ryzhov

et al. 2024

Annals RAMS

View full text Add to dashboard Cite

show abstract

Modeling of the Potential Effect of Revaccination against Whooping Cough in Children Aged 6–7 and 14 years within the Framework of the National of preventive vaccinations

Брико

Mindlina

Mikheeva

et al. 2021

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

Relevance. Currently, the national calendar of preventive vaccinations does not provide for revaccination against whooping cough in children over the age of 18 months. At the same time, the epidemiological and economic feasibility of revaccination against whooping cough in children aged 6–7 years, as well as adolescents, has been demonstrated in world practice. Aim. Based on a mathematical model, develop a forecast of pertussis morbidity dynamics and assess the potential socio-economic damage under the current and expanded vaccine prophylaxis algorithms.Methods. Mathematical modeling of the potential effect of revaccination against whooping cough in children aged 6–7 years (scenario 1) and at 6–7 years and 14 years (scenario 2) was carried out within the framework of the national calendar of preventive vaccinations. A simulation dynamic mathematical model is constructed that allows predicting the development of the epidemiological process of whooping cough on the basis of the dynamics of the main indicators of its prevalence in the population that developed in previous years. The model took into account dynamic changes in the preventive effectiveness of vaccinations and the potential level of underestimation of morbidity. The obtained arrays of indicators served as the basis for extrapolating trends in morbidity and mortality until 2034.The calculation of epidemiological benefits was carried out in the metrics of prevented loss of years of life under the two scenarios under consideration in comparison with the current vaccination algorithm. The calculation of the economic effect was carried out on the basis of the obtained indicators of epidemiological benefits in the metrics of the monetary equivalent of the average cost of a year of life, taking into account the projected inflation coefficients until 2034.Results. The projected decrease in the number of years of life lived in a state of illness, in comparison with the current situation, will total 44.5 thousand years for the period 2019–2034 under scenario 1 and 66.7 thousand years under scenario 2. The socio-economic damage from prevented cases of the disease, expressed in the monetary equivalent of the average cost of living, will decrease by 28.6% (scenario 1) or 42.0% (scenario 2).Conclusions. A comparison of the received public benefits with the costs of vaccination shows that the expansion of the NCPP with additional revaccinations against whooping cough (at 6–7 years or at 6–7 and at 14 years) is advisable both in epidemiological and economic aspects.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Clinical and diagnostic features of pertussis in older children

Cited by 2 publications

References 0 publications

Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates

Vaccine-Induced Immunity Against Pertussis in Lung Transplant Candidates

Modeling of the Potential Effect of Revaccination against Whooping Cough in Children Aged 6–7 and 14 years within the Framework of the National of preventive vaccinations

Contact Info

Product

Resources

About